Table 4.

Outcome of consolidation trial

ICE
IcE
Total
%
95% CI
%
95% CI
%
95% CI
RFS at 3 years       
    All cases   49   40-59   46   37-56   48   41-55  
    Favorable cytogenetics   76   50-91   69   43-86   72   55-85  
    Intermediate cytogenetics   47   35-58   47   36-58   47   39-55  
    Adverse cytogenetics   0   —   20*  5-54   15*  4-45  
    Unknown cytogenetics   33   8-73   20†  3-69   27   9-59  
Survival at 3 years       
    All cases   61   51-71   62   52-71   62   55-68  
    Favorable cytogenetics   88   63-97   79   50-93   84   66-93  
    Intermediate cytogenetics   59   47-70   65   53-75   62   53-69  
    Adverse cytogenetics   33   4-85   33*  10-70   35   13-65  
    Unknown cytogenetics
 		 33
 		 8-73
 		 0
 		 —
 		 23
 		 6-57
 
ICE
IcE
Total
%
95% CI
%
95% CI
%
95% CI
RFS at 3 years       
    All cases   49   40-59   46   37-56   48   41-55  
    Favorable cytogenetics   76   50-91   69   43-86   72   55-85  
    Intermediate cytogenetics   47   35-58   47   36-58   47   39-55  
    Adverse cytogenetics   0   —   20*  5-54   15*  4-45  
    Unknown cytogenetics   33   8-73   20†  3-69   27   9-59  
Survival at 3 years       
    All cases   61   51-71   62   52-71   62   55-68  
    Favorable cytogenetics   88   63-97   79   50-93   84   66-93  
    Intermediate cytogenetics   59   47-70   65   53-75   62   53-69  
    Adverse cytogenetics   33   4-85   33*  10-70   35   13-65  
    Unknown cytogenetics
 		 33
 		 8-73
 		 0
 		 —
 		 23
 		 6-57
 

There were 99 patients in the ICE group, 103 in the IcE group, and 202 patients total. RFS indicates relapse-free survival; —, not applicable; and survival, measured from the time of consolidation randomization.

*

At 2.6 years, longest surviving patient not followed beyond this time.

†

At 1.9 years, longest surviving patient not followed beyond this time.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal